Aarkstore - Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014 - PowerPoint PPT Presentation

About This Presentation
Title:

Aarkstore - Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Description:

Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Peregrine Pharmaceuticals, Inc.’s pharmaceutical research and development focus. – PowerPoint PPT presentation

Number of Views:110

less

Transcript and Presenter's Notes

Title: Aarkstore - Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014


1
Peregrine Pharmaceuticals, Inc. - Product
Pipeline Review - 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/63685/peregrine-pharmaceuticals-inc-product-pipe
    line-review

2
Peregrine Pharmaceuticals, Inc. - Product
Pipeline Review - 2014
3
Summary
  • Global Markets Directs, Peregrine
    Pharmaceuticals, Inc. - Product Pipeline Review -
    2014, provides an overview of the Peregrine
    Pharmaceuticals, Inc.s pharmaceutical research
    and development focus.
  •  This report provides comprehensive information
    on the current therapeutic developmental pipeline
    of Peregrine Pharmaceuticals, Inc.s, complete
    with comparative analysis at various stages,
    therapeutics assessment by drug target, mechanism
    of action (MoA), route of administration (RoA)
    and molecule type. It also reviews latest
    updates, and featured news and press releases,
    along with special features on late-stage and
    discontinued projects.
  • Peregrine Pharmaceuticals, Inc. - Product
    Pipeline Review - 2014report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications. The report is built using data and
    information sourced from Global Markets Directs
    proprietary databases, Company/University
    websites, SEC filings, investor presentations and
    featured press releases from company/university
    sites and industry-specific third party sources,
    put together by Global Markets Directs team.

4
Summary
  • Drug profiles/records featured in the report
    undergoes periodic updation following a stringent
    set of processes that ensures that all the
    profiles are updated with the latest set of
    information. Additionally, processes including
    live news deals tracking, browser based
    alert-box and clinical trials registries tracking
    ensure that the most recent developments are
    captured on a real time basis.
  •  
  • The report enhances decision making capabilities
    and help to create effective counter strategies
    to gain competitive advantage. It strengthens RD
    pipelines by identifying new targets and MOAs to
    produce first-in-class and best-in-class
    products.
  •  
  • Note Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated disease.

5
Scope
  • - The report provides brief overview of Peregrine
    Pharmaceuticals, Inc. including business
    description, key information and facts, and its
    locations and subsidiaries
  • - The report reviews current pipeline of
    Peregrine Pharmaceuticals, Inc.s human
    therapeutic division and enlists all their major
    and minor projects
  • - The report features product description and
    descriptive mechanism of action for key pipeline
    products along with the products developmental
    history and major milestones
  • - Special feature on out-licensed and partnered
    product portfolio
  • - The report summarizes all the dormant and
    discontinued pipeline projects
  • - Latest company statement
  • - Latest news and deals relating to the Peregrine
    Pharmaceuticals, Inc.s pipeline products

6
Reasons to buy
  • - Evaluate Peregrine Pharmaceuticals, Inc.s
    strategic position with total access to detailed
    information on its product pipeline
  • - Assess the growth potential of Peregrine
    Pharmaceuticals, Inc. in its therapy areas of
    focus
  • - Identify new drug targets and therapeutic
    classes in the Peregrine Pharmaceuticals, Inc.s
    RD portfolio and develop key strategic
    initiatives to reinforce pipeline in those areas
  • - Exploit in-licensing opportunities by
    identifying windows of opportunity to fill
    portfolio gaps
  • - Develop strategic initiatives by understanding
    the focus areas of Peregrine Pharmaceuticals,
    Inc. and exploit collaboration and partnership
    opportunities
  • - Identify emerging players with potentially
    strong product portfolio and create effective
    counter-strategies to gain competitive advantage
  • - Plan mergers and acquisitions effectively by
    identifying the most promising pipeline of
    Peregrine Pharmaceuticals, Inc.

7
Table of Content
List of Tables 3List of Figures 4Peregrine
Pharmaceuticals, Inc. Snapshot 5Peregrine
Pharmaceuticals, Inc. Overview 5Key Information
5Key Facts 5Peregrine Pharmaceuticals, Inc. -
Research and Development Overview 6Key
Therapeutic Areas 6Peregrine Pharmaceuticals,
Inc. - Pipeline Review 9Pipeline Products by
Stage of Development 9Pipeline Products -
Monotherapy 10Pipeline Products - Partnered
Products 11Partnered Products/Combination
Treatment Modalities 12Pipeline Products -
Out-Licensed Products 13
8
Table of Content
Out-Licensed Products/Combination Treatment
Modalities 14Peregrine Pharmaceuticals, Inc. -
Pipeline Products Glance 15Peregrine
Pharmaceuticals, Inc. - Late Stage Pipeline
Products 15Phase III Products/Combination
Treatment Modalities 15Peregrine
Pharmaceuticals, Inc. - Clinical Stage Pipeline
Products 16Phase II Products/Combination
Treatment Modalities 16Phase I
Products/Combination Treatment Modalities
17Peregrine Pharmaceuticals, Inc. - Early Stage
Pipeline Products 18Preclinical
Products/Combination Treatment Modalities
18Discovery Products/Combination Treatment
Modalities 19Peregrine Pharmaceuticals, Inc. -
Drug Profiles 20bavituximab 20
9
List Of Tables
  • Peregrine Pharmaceuticals, Inc., Key Information
    5Peregrine Pharmaceuticals, Inc., Key Facts
    5Peregrine Pharmaceuticals, Inc. - Pipeline by
    Indication, 2014 8Peregrine Pharmaceuticals,
    Inc. - Pipeline by Stage of Development, 2014
    9Peregrine Pharmaceuticals, Inc. - Monotherapy
    Products in Pipeline, 2014 10Peregrine
    Pharmaceuticals, Inc. - Partnered Products in
    Pipeline, 2014 11Peregrine Pharmaceuticals, Inc.
    - Partnered Products/ Combination Treatment
    Modalities, 2014 12Peregrine Pharmaceuticals,
    Inc. - Out-Licensed Products in Pipeline, 2014
    13Peregrine Pharmaceuticals, Inc. - Out-Licensed
    Products/ Combination Treatment Modalities, 2014
    14Peregrine Pharmaceuticals, Inc. - Phase III,
    2014 15Peregrine Pharmaceuticals, Inc. - Phase
    II, 2014 16Peregrine Pharmaceuticals, Inc. -
    Phase I, 2014 17  

10
List of Figures
  • Peregrine Pharmaceuticals, Inc. - Pipeline by Top
    10 Indication, 2014 7Peregrine Pharmaceuticals,
    Inc. - Pipeline by Stage of Development, 2014
    9Peregrine Pharmaceuticals, Inc. - Monotherapy
    Products in Pipeline, 2014 10Peregrine
    Pharmaceuticals, Inc. - Partnered Products in
    Pipeline, 2014 11Peregrine Pharmaceuticals, Inc.
    - Out-Licensed Products in Pipeline, 2014
    13Peregrine Pharmaceuticals, Inc. - Pipeline by
    Top 10 Target, 2014 28Peregrine Pharmaceuticals,
    Inc. - Pipeline by Top 10 Route of
    Administration, 2014 29Peregrine
    Pharmaceuticals, Inc. - Pipeline by Top 10
    Molecule Type, 2014 30Peregrine Pharmaceuticals,
    Inc. - Pipeline Products by Top 10 Mechanism of
    Action, 2014 31

11
Related Reports
  • Global Neurosurgery Market 2015-2019
  • Active Pharmaceutical Ingredients (API) Market in
    India 2015-2019
  • BrainStorm Cell Therapeutics Inc. (BCLI) -
    Financial and Strategic SWOT Analysis Review
  • Ampio Pharmaceuticals, Inc. (AMPE) - Financial
    and Strategic SWOT Analysis Review
  • MiMedx Group, Inc (MDXG) - Financial and
    Strategic SWOT Analysis Review

12
Related Reports
  • Threshold Pharmaceuticals, Inc. (THLD) -
    Financial and Strategic SWOT Analysis Review
  • MEI Pharma, Inc. (MEIP) - Financial and Strategic
    SWOT Analysis Review
  • Titan Pharmaceuticals, Inc. (TTNP) - Financial
    and Strategic SWOT Analysis Review
  • RedHill Biopharma Ltd. (RDHL) - Financial and
    Strategic SWOT Analysis Review
  • Pharmaceuticals Healthcare Market Research
    Reports

13
  • Peregrine Pharmaceuticals, Inc. - Product
    Pipeline Review 2014
  • Published Oct 2014 44 Pages
  • Peregrine Pharmaceuticals, Inc. - Product
    Pipeline Review - 2014report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications.
    Price

Format Price
PDF 1500
Site Licence 3000
Enterprise Wide Licence 4500
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
Write a Comment
User Comments (0)
About PowerShow.com